Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of Amivantamab (JNJ61186372), a Human Bispecific EGFR and cMet Antibody, in Par… Ended

2023-509435-11-00 Advanced Non-Small Cell Lung Cancer 1 2019-02-21
A Study of Durvalumab Before and After Surgery for Patients with Operable Non-Small Cell Lung Cancer. Ended

2023-509576-42-00 Patients with resectable Non-small Cell Lung Cancer (St 5 2019-02-21
Study on Olaparib Plus Abiraterone as First-line Therapy in Men with Metastatic Castration-resistant Prostate Cancer Ended

2024-511144-86-00 Metastatic castration-resistant prostate cancer 5 2019-02-14
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors Ended

2023-503812-34-00 Locally Advanced or Metastatic Disease in Solid Tumors 4 2019-02-13
This is a Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatmen… Ended

2023-510015-19-00 Patients with histologically or cytologically documente 5 2019-02-11
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Foll… Ended

2023-509602-29-00 Patients with Limited Stage Small-Cell Lung Cancer (LS- 5 2019-02-11
DORA Trial: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC) Ended

2024-513867-19-00 metastatic Castration-Resistant Prostate Cancer (mCRPC) 5 2019-01-31
Testing a new targeted therapy trastuzumab deruxtecan (DS-8201a) against ado-trastuzumab emtansine (T-DM1) for patients with advanced stage … Ended

2024-511204-16-00 Metastatic breast cancer 5 2019-01-23
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer Ended

2023-506777-36-00 Prostate Cancer 10 2019-01-04
A Study of Zolbetuximab (IMAB362) plus CAPOX in Adults with Gastric Cancer. Ended

2024-511648-16-00 Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Adv 5 2019-01-04
REVOLUTION - Randomized phasE 2 study of Valproic acid in combination with bevacizumab and Oxaliplatin/fLUoropyrimidine regimens in patients… Ended

2024-516844-25-01 Patients with ras-mutated metastatIc colorectal cancer 4 2019-01-03
A Phase I/II Study of Paclitaxel plus Carboplatin and Durvalumab (MEDI4736) with or without Oleclumab (MEDI9447) for Previously Untreated Lo… Ended

2024-511850-34-00 Previously untreated locally recurrent inoperable or me 9 2019-01-02
An Open-Label Phase 2 study to evaluate the effect of PT2977 for the treatment of von Hippel-Lindau Disease-Associated with kidney cancer Ended

2023-509119-99-00 Von Hippel-Lindau disease-associated Renal Cell Carcino 4 2019-01-02
Phase III study of pembrolizumab for high-risk early-stage ER+/HER2– breast cancer Ended

2023-506921-12-00 ER+/HER2- Breast Cancer 5 2018-12-27
A Study of combination of Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) compared to VELCADE, Lenalidomide, and … Ended

2023-506125-10-00 Multiple Myeloma 5 2018-12-24
Irinotecan-based triplet (FOLFOXIRI) as perioperative treatment in resectable gastric and gastroesophageal junction adenocarcinoma - a phase… Ended

2023-509044-96-00 Resectabel gastric and gastroesophageal junction adenoc 4 2018-12-21
MK-3475 (SCH 9000475) as neoadjuvant and adjuvant therapy in Stage III-IVA resectable LA HNSCC (Locoregionally Advanced Head and Neck Squamo… Ended

2022-500254-41-00 Stage III-IVA Resectable Locoregionally Advanced Head a 5 2018-12-13
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treat… Ended

2024-513912-89-00 Primary Or Secondary (Post-PV MF or Post-ET-MF) Myelofi 10 2018-12-13
A trial to learn how well durvalumab and chemotherapy with or without tremelimumab work in adults with advanced cancer of the bladder or uri… Ended

2024-510976-19-00 Patients with Unresectable Locally Advanced or Metastat 5 2018-11-30
A Phase 3 trial of BCG with or without pembrolizumab for High Risk Non Muscle Invasive Bladder Cancer Ended

2022-501817-29-00 High Risk Non-muscle invasive bladder cancer 5 2018-11-27
A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus mFOLFOX6 Compared with Placebo Plus… Ended

2024-511365-11-00 Metastatic Gastric or Gastroesophageal Junction (GEJ) A 5 2018-11-27
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Bas… Ended

2024-516662-11-00 Ovarian epithelial cancer 5 2018-11-23
A STUDY OF EFFICACY AND SAFETY OF LONG-ACTING LOW DOSE ROPEGINTERFERON IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH BOSUTINIB FROM… Ended

2024-517417-32-00 CHRONIC MYELOID LEUKEMIA 4 2018-11-22
Treatment with carfilzomib, lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with high-risk smoldering Multi… Ended

2024-511334-12-00 Smoldering Multiple Myeloma 4 2018-11-19